Loading
Haemonetics Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by KROLL MARK W, was filed 12 Nov 2025.
Haemonetics Corp: what insiders have been doing
Haemonetics Corp, founded in 1971, is a Healthcare & Pharma company based in Boston, United States. Its directors and officers file their transactions with SEC (Form 4). In the past year (19 October 2025 to 19 October 2026), 10 filings came from 9 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €86k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €86k, bought by Kroll Mark W and made public on 12 November 2025. The buyers include 1 senior executive.
The latest purchase dates back some time: it was published 343 days ago, on 12 November 2025. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
With 10 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Looking back to 2016, when coverage begins, insiders filed 1 purchase and 54 sales. For the fiscal year to 28 March 2026, the annual 10-K puts revenue at 1.33 bn USD and net income at 97.3 m USD.
In the same sector, recent insider purchases at Vivos Inc and Anixa Biosciences Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
210
Thresholds
n/a
Buy Volume
€85,573
1 ops. · all time
Sell Volume
€4M
54 ops. · all time
Who traded when
BuySaleMark W. Kroll1 buy
Since the insiders bought
- -22.2%Entry US$73.91 · Close at T+90 US$57.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Haemonetics Corp Buy (bullish), based on 10 analysts. Average price target: US$124.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,111 of 26,279 companies
49.4
score / 100
Value41
Quality58
FCF yld4.8%
Earn yld1.8%
EV/EBITDA24.7x
ROE11%
Gross mgn59%
Net mgn7.3%
Debt/EBITDA4.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$118.28
Analyst consensus
10 analystsBuy
US$86.00Target US$124.50(+5%)US$142.00
Income statement
RevenueUS$1.3B
Gross profitUS$787.6M59% margin
EBITDAUS$268.5M20% margin
Net incomeUS$97.3M7.1% margin
Valuation
PER (trailing)57.1x
PER (forward)20.5x
P/Book6.4x
Beta0.61
Balance sheet & cash
Market capUS$5.4B
Total debtUS$1.2B
Free Cash FlowUS$260.4M
Debt / Equity140%
Profitability & ownership
ROE11.2%
ROA6.6%
% insiders1.3%
% institutions112.5%
Last declaration on 28 July 2026
Declarations210 total
2,538 sharesCommon StockSEC:0000313143-26-000099:0
2,538 sharesCommon StockSEC:0000313143-26-000101:0
2,538 sharesCommon StockSEC:0000313143-26-000105:0
2,538 sharesCommon StockSEC:0000313143-26-000111:0
2,538 sharesCommon StockSEC:0000313143-26-000112:0
2,538 sharesCommon StockSEC:0000313143-26-000107:0
2,538 sharesCommon StockSEC:0000313143-26-000109:0
2,538 sharesCommon StockSEC:0000313143-26-000103:0
1,400 shares@ US$70.568.8% of flowCommon StockSEC:0000313143-25-000078:0
Canonical exit: 8 Feb 2026 (T+90)
145 shares@ US$50.0110.2% of flowCommon StockSEC:0000313143-25-000064:0
238 shares@ US$49.956.8% of flowCommon StockSEC:0000313143-25-000061:0
2,693 sharesCommon StockSEC:0001127602-25-019593:0
2,693 sharesCommon StockSEC:0001127602-25-019599:0
2,693 sharesCommon StockSEC:0001127602-25-019598:0
2,693 sharesCommon StockSEC:0001127602-25-019596:0
2,693 sharesCommon StockSEC:0001127602-25-019595:0
2,693 sharesCommon StockSEC:0001127602-25-019594:0
2,693 sharesCommon StockSEC:0001127602-25-019592:0
2,693 sharesCommon StockSEC:0001127602-25-019591:0
6,755 sharesCommon StockSEC:0001127602-25-017498:0
5,689 sharesCommon StockSEC:0001127602-25-017492:0
3,195 sharesCommon StockSEC:0001127602-25-017104:0
2,662 sharesCommon StockSEC:0001127602-25-017102:0
66,666 shares0Common StockSEC:0001127602-25-016532:0
12,221 shares0Common StockSEC:0001127602-25-016517:0
25 of 210 declarations
About Haemonetics Corp
Haemonetics Corp. (NYSE: HAE) is a United States–based, publicly listed medical technology company focused on blood collection, plasma processing, and hospital hemostasis management solutions. Founded in 1971, the company has built a long operating history around a core franchise in apheresis and blood-component technologies, then expanded into a broader platform serving plasma centers, blood centers, and hospitals. Its global headquarters is in Boston, Massachusetts, reflecting a recent consolidation of corporate functions in the Boston area. ([haemonetics.com](https://www.haemonetics.com/about-us?utm_source=openai))
Haemonetics’ business model is organized around several complementary product and service lines. On one side, it offers end-to-end plasma collection technologies designed to improve the productivity and operating efficiency of plasma centers. It also supplies products and systems used by blood centers to collect in-demand blood components. On the hospital side, the company markets hemostasis management and transfusion-related solutions, including diagnostic instruments and software that help clinicians assess bleeding and clotting risk, monitor antithrombotic therapy, and manage blood products more efficiently. Key brands include TEG, Haemonetics’ well-known viscoelastic hemostasis testing platform, BloodTrack for hospital blood management, and the VASCADE family for vascular closure. ([haemonetics.com](https://www.haemonetics.com/about-us?utm_source=openai))
Read moreShow less
From a competitive standpoint, Haemonetics occupies a specialized niche with meaningful technology and workflow barriers. Its value proposition combines capital equipment, consumables, software, and service, which can support sticky customer relationships and recurring revenue characteristics. The company emphasizes innovation across product, software, and market development, supported by clinical, medical, and regulatory capabilities. Over time, it has built an international footprint and describes itself as a global medical technology company serving customers across multiple geographies. ([haemonetics.com](https://www.haemonetics.com/about-us/corporate-responsibility/our-society?utm_source=openai))
Recent developments suggest a portfolio focused on higher-quality growth and margin improvement. In fiscal 2025, management said the company continued to see strong demand for apheresis products in blood centers while divesting its Whole Blood product line, a move intended to better align resources toward higher-margin, higher-growth opportunities. More recently, Haemonetics announced its fourth-quarter and fiscal 2026 financial results on May 7, 2026, and also highlighted participation in the Bank of America 2026 Healthcare Conference. In April 2026, the company disclosed a new study highlighting the safety and efficacy profile of VASCADE MVP XL in large-bore venous access closure procedures, reinforcing the ongoing clinical positioning of its vascular closure franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/313143/000031314325000041/hae-20250605.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
